leisure time -WSS

leisure time

author：comprehensive 2025-10-01 00:17:35 - browse：19437

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Paxlovid should be available without a positive Covid test

focus

WSS

Medicaid, Medicare dual

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Watch the official trailer for 'Ahsoka' series

Menendez indictment could see pharma lose a key ally

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

Ionis has late

Drug repurposing or repositioning? The language matters

Blinken talks high

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Hollywood unions extend contract negotiations for actors

Watch the official trailer for 'Ahsoka' series

What does generative AI mean for health care? We asked experts

Listen: Who gets the credit for GLP

focus

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Address the ethical violations that led to 'Three Identical Strangers'

FDA advisers vote against ALS treatment from BrainStorm

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Menendez indictment could see pharma lose a key ally

Would Medicare drug price negotiations stall in a shutdown?

hotspot

explore

focus

explore